ORAMED PHARMACEUTICALS INC.: 10-Q filed 2012-12-26
What ORAMED PHARMACEUTICALS INC. reported in its quarterly report filed 2012-12-26 (fiscal Q1 2013): 24 published measures, 70 facts as tagged in accession 0001178913-12-003519.
This filing
- Form
- 10-Q (quarterly report)
- Filed
- 2012-12-26
- Fiscal period
- fiscal Q1 2013
- Accession
- 0001178913-12-003519 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All ORAMED PHARMACEUTICALS INC. filings.
Reported measures
Total assets
Resources recognized on the balance sheet. Book assets are not the market value of the business.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2012-11-30 | 6,824,867 | USD | |
| At 2012-08-31 | 5,294,851 | USD |
Stockholders equity
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2012-11-30 | 6,249,867 | USD | |
| At 2012-08-31 | 3,778,013 | USD | |
| At 2011-08-31 | 3,723,916 | USD | |
| At 2010-08-31 | 830,272 | USD | |
| At 2009-08-31 | 2,746,192 | USD | |
| At 2008-08-31 | 4,593,060 | USD | |
| At 2002-04-11 | 53,700 | USD |
Cash and cash equivalents
Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2012-11-30 | 5,531,075 | USD | |
| At 2012-08-31 | 4,430,740 | USD | |
| At 2011-11-30 | 1,495,615 | USD | |
| At 2011-08-31 | 1,513,365 | USD |
Net income or loss
Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2012-09-01 to 2012-11-30 | -958,753 | USD | 91 |
| 2002-04-12 to 2012-11-30 | -18,850,530 | USD | 3886 |
| 2011-09-01 to 2012-08-31 | -3,344,478 | USD | 366 |
| 2011-09-01 to 2011-11-30 | -478,519 | USD | 91 |
| 2010-09-01 to 2011-08-31 | -1,561,245 | USD | 365 |
| 2009-09-01 to 2010-08-31 | -2,977,376 | USD | 365 |
| 2008-09-01 to 2009-08-31 | -2,760,474 | USD | 365 |
| 2007-09-01 to 2008-08-31 | -2,769,271 | USD | 366 |
| 2002-04-12 to 2007-08-31 | -4,478,917 | USD | 1968 |
Operating cash flow
Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2012-09-01 to 2012-11-30 | -792,826 | USD | 91 |
| 2002-04-12 to 2012-11-30 | -11,073,790 | USD | 3886 |
| 2011-09-01 to 2011-11-30 | -484,070 | USD | 91 |
Capital expenditure payments
Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2002-04-12 to 2012-11-30 | 125,612 | USD | 3886 |
Financing cash flow
Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2012-09-01 to 2012-11-30 | 1,458,436 | USD | 91 |
| 2002-04-12 to 2012-11-30 | 16,950,375 | USD | 3886 |
Investing cash flow
Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2012-09-01 to 2012-11-30 | 454,227 | USD | 91 |
| 2002-04-12 to 2012-11-30 | -288,476 | USD | 3886 |
| 2011-09-01 to 2011-11-30 | 448,939 | USD | 91 |
Retained earnings or deficit
Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2012-11-30 | -18,850,530 | USD | |
| At 2012-08-31 | -17,891,777 | USD |
Income tax expense or benefit
Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2002-04-12 to 2012-11-30 | 240,776 | USD | 3886 |
Net property, plant and equipment
Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2012-11-30 | 2,497 | USD | |
| At 2012-08-31 | 4,768 | USD |
Share-based compensation expense
Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2012-09-01 to 2012-11-30 | 218,208 | USD | 91 |
| 2002-04-12 to 2012-11-30 | 5,189,495 | USD | 3886 |
| 2011-09-01 to 2011-11-30 | 51,296 | USD | 91 |
Operating income or loss
Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2012-09-01 to 2012-11-30 | -731,839 | USD | 91 |
| 2002-04-12 to 2012-11-30 | -18,860,956 | USD | 3886 |
| 2011-09-01 to 2011-11-30 | -465,917 | USD | 91 |
Current assets
Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2012-11-30 | 6,807,889 | USD | |
| At 2012-08-31 | 5,276,476 | USD |
Current liabilities
Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2012-11-30 | 334,554 | USD | |
| At 2012-08-31 | 644,425 | USD |
Net current accounts receivable
Current customer receivables after the allowance for credit loss. The balance is not cash collected or a guarantee of collection.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2012-11-30 | 75,950 | USD | |
| At 2012-08-31 | 87,691 | USD |
Research and development expense
Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2012-09-01 to 2012-11-30 | 392,626 | USD | 91 |
| 2002-04-12 to 2012-11-30 | 9,925,320 | USD | 3886 |
| 2011-09-01 to 2011-11-30 | 184,016 | USD | 91 |
Common shares outstanding
Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2012-11-30 | 86,505,020 | shares | |
| At 2012-08-31 | 80,075,725 | shares |
Accumulated other comprehensive income or loss
Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2012-11-30 | 235,868 | USD |
Pre-tax income or loss from continuing operations
Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2012-09-01 to 2012-11-30 | -958,753 | USD | 91 |
| 2002-04-12 to 2012-11-30 | -18,609,754 | USD | 3886 |
| 2011-09-01 to 2011-11-30 | -478,519 | USD | 91 |
Comprehensive income or loss
Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2012-09-01 to 2012-11-30 | -722,885 | USD | 91 |
| 2002-04-12 to 2012-11-30 | -18,614,662 | USD | 3886 |
| 2011-09-01 to 2011-11-30 | -474,314 | USD | 91 |
| 2002-04-12 to 2007-08-31 | -16 | USD | 1968 |
General and administrative expense
General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2012-09-01 to 2012-11-30 | 339,213 | USD | 91 |
| 2002-04-12 to 2012-11-30 | 8,500,760 | USD | 3886 |
| 2011-09-01 to 2011-11-30 | 281,901 | USD | 91 |
Depreciation expense
Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2012-09-01 to 2012-11-30 | 2,271 | USD | 91 |
| 2002-04-12 to 2012-11-30 | 123,115 | USD | 3886 |
| 2011-09-01 to 2011-11-30 | 6,042 | USD | 91 |
Change in accounts payable
The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2012-09-01 to 2012-11-30 | -309,870 | USD | 91 |
| 2002-04-12 to 2012-11-30 | 287,303 | USD | 3886 |
| 2011-09-01 to 2011-11-30 | -16,920 | USD | 91 |
Inspect the source
- Entity
- ORAMED PHARMACEUTICALS INC. / CIK 0001176309
- Captured
- 2026-09-20T07:44:51.277Z
- SEC response SHA-256
4de2fa61f6e99a9334450df93c3a54e105e138fae12a8b631b4bdc95f4c98422
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001176309.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))